BASE 10 GENETICS INC RNAstill Molecular Transport Medium Vial, Catalog number MTM-001, a component of the following catalog numbers of RNAstill MTM specimen collection kits: MTM-SW03 with Oropharyngeal swab and MTMSW-05 with Nasopharyngeal swab, packaged 25 specimen collection kits per plastic sleeve. RNAstill Molecular Transport Medium (MTM) safely deactivates pathogens at the point of collection and stabilizes RNA and DNA, allowing safe transport of specimens at ambient temperature from the collection site to th Recall
Check Your Product
According to the U.S. Food and Drug Administration (FDA)
Product
RNAstill Molecular Transport Medium Vial, Catalog number MTM-001, a component of the following catalog numbers of RNAstill MTM specimen collection kits: MTM-SW03 with Oropharyngeal swab and MTMSW-05 with Nasopharyngeal swab, packaged 25 specimen collection kits per plastic sleeve. RNAstill Molecular Transport Medium (MTM) safely deactivates pathogens at the point of collection and stabilizes RNA and DNA, allowing safe transport of specimens at ambient temperature from the collection site to th
Brand
BASE 10 GENETICS INC
Lot Codes / Batch Numbers
Catalog #MTM-SW03: Lot numbers MG18401, MG18409, HH04806, KM02643, MG27906, MG28502, MG30295, and MG33903. Catalog #MTM-SW05: Lot numbers MG18401, MG18408, MG27901, and KC28836.
Products Sold
Catalog #MTM-SW03: Lot numbers MG18401, MG18409, HH04806, KM02643, MG27906, MG28502,MG30295, and MG33903. Catalog #MTM-SW05: Lot numbers MG18401, MG18408, MG27901, and KC28836.
BASE 10 GENETICS INC is recalling RNAstill Molecular Transport Medium Vial, Catalog number MTM-001, a component of the following catal due to The product does not have 510(k) clearance.. Based on FDA medical device recall database.
Summary derived from FDA notice
Reason for Recall
As stated by FDA
The product does not have 510(k) clearance.
Recommended Action
Per FDA guidance
The recalling firm issued letters dated 1/10/2022 to the main office locations of the end-user facilities explaining the reason for recall, hazard involved, and requesting they discontinue use per their instruction on 11/30/2021. (The main office locations were only instructed to discontinue use at that time and the product was not under recall then.) The letter requested return of the kits as soon as possible and the firm's Client Success team will contact the end-user facilities to provide detailed instructions to complete and return. An Acknowledgement and Receipt Form was enclosed for completion and return via email to the firm. The Client Success Team began sending follow-up emails to the end-user facilities on 1/11/2022 which provided the number of kits the firm should have and that they should be returned by 1/21/2022. Attached was a return shipping label and a guide with additional details on how to return the kits. The follow-up email also contained the reason for recall and hazard involved. The home office for the end-user facilities sent out emails beginning 1/11/2022 to their end-user facilities containing the subject line "COVID-19 UPDATE: Base10 Test Kit Recall Instructions." The email contained an advisory which said facilities should not be discarding old Base10 test kits that were discontinued for use. It also said that Base 10 will be performing a recall on all RBC Kits beginning today and the end user will receive formal notification from Base 10 as well. Return instructions were sent with the email.
Verify this information on the official source
For complete details and official instructions, check the U.S. Food and Drug Administration (FDA) directly.
View official FDA recall noticePage updated: Jan 10, 2026